abstract |
Disclosed is a use of (a) at least one sterol absorption inhibitor or at least one 5alpha-stanol absorption inhibitor and (b) at least one cholesterol biosynthesis inhibitor in the preparation of a medicament for simultaneous, separate or sequential use for treating vascular inflammation in a subject, having a blood level of c-reactive protein of greater than about 0.4 mg/dL. |